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To detect early response to sunitinib treatment in metastatic clear cell renal cancer (mRCC)
using multiparametric MRI.
Method
Participants with mRCC undergoing pre-surgical sunitinib therapy in the prospective Neo-
Sun clinical trial (EudraCtNo: 2005-004502-82) were imaged before starting treatment, and
after 12 days of sunitinib therapy using morphological MRI sequences, advanced diffusion-
weighted imaging, measurements of R2* (related to hypoxia) and dynamic contrast-
enhanced imaging. Following nephrectomy, participants continued treatment and were fol-
lowed-up with contrast-enhanced CT. Changes in imaging parameters before and after
sunitinib were assessed with the non-parametric Wilcoxon signed-rank test and the log-rank
test was used to assess effects on survival.
Results
12 participants fulfilled the inclusion criteria. After 12 days, the solid and necrotic tumor vol-
umes decreased by 28% and 17%, respectively (p = 0.04). However, tumor-volume reduc-
tion did not correlate with progression-free or overall survival (PFS/OS). Sunitinib therapy
resulted in a reduction in median solid tumor diffusivity D from 1298x10-6 to 1200x10-6mm2/
s (p = 0.03); a larger decrease was associated with a better RECIST response (p = 0.02)
and longer PFS (p = 0.03) on the log-rank test. An increase in R2* from 19 to 28s-1 (p =
0.001) was observed, paralleled by a decrease in Ktrans from 0.415 to 0.305min-1 (p = 0.01)
and a decrease in perfusion fraction from 0.34 to 0.19 (p<0.001).
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Conclusions
Physiological imaging confirmed efficacy of the anti-angiogenic agent 12 days after initiating
therapy and demonstrated response to treatment. The change in diffusivity shortly after
starting pre-surgical sunitinib correlated to PFS in mRCC undergoing nephrectomy, how-




Renal Cell Carcinoma (RCC) is the most common malignant tumor of the kidney, with prog-
nosis being highly stage-dependent. Despite the increasing detection of early-stage RCC as an
incidental finding on cross-sectional imaging, 15–20% of patients still present with advanced,
stage IV disease [1, 2]. 5-year overall survival (OS) exceeds 80% in patients diagnosed with
stage I and II RCC, however, the prognosis of patients with locally advanced or metastatic
RCC (mRCC) has a far lower 5-year OS at 11.3% [1, 2].
The therapeutic spectrum for advanced and metastatic RCC has expanded rapidly over the
past decade. Whilst vascular endothelial growth factor (VEGF)-targeted therapy combined
with an immune-checkpoint inhibitor has become the standard-of-care in fit patients with
mRCC, (VEGF)-targeted therapy like sunitinib continues to be used in all lines of treatment
[3, 4]. Expansion in the therapeutic options of mRCC requires a parallel improvement in
methods of early detection of therapy response to optimize the time spent on effective therapy
and reduce side-effects and costs in the absence of clinical benefit.
Current guidelines suggest two to four-monthly follow-up of mRCC patients on systemic
therapy with contrast-enhanced CT for response assessment according to the Response Evalua-
tion Criteria in Solid Tumors (RECIST 1.1) [5]. However, these criteria have well-known limita-
tions, and there is no clinical evidence that RECIST-defined disease progression is a clinically
valid endpoint that requires treatment interruption or modification [3]. Additionally, patterns of
treatment response to immunotherapy and targeted therapy differ from cytotoxic chemotherapy
where volume-effects predominate, and are insufficiently captured by RECIST at early time
points [6]. While survival is correlated with volumetric response in mRCC, even stabilization of
the disease is a valuable achievement, which is, however, difficult to detect morphologically [7, 8].
An early marker of response to VEGF-targeted treatment with tyrosine kinase inhibitors
(TKI) would allow a switch to alternative anti-cancer therapy before the tumor burden
increases in patients who derive no benefit from TKI. The mechanism of action of VEGF-tar-
geted TKI like sunitinib, namely inhibition of tumor angiogenesis and vascular maintenance,
supports the use of physiological MRI for the early detection of treatment response [9]. Intra-
voxel incoherent motion-type diffusion-weighted imaging (IVIM-DWI) can differentiate the
contribution of microperfusion and tissue diffusion to the overall diffusion signal [10]. Mean-
while, blood oxygen level-dependent (BOLD) MRI is sensitive to tissue hypoxia, which has
been shown to increase following sunitinib treatment in melanoma xenografts [11, 12]. Finally,
tissue perfusion can be assessed using dynamic contrast-enhanced (DCE) MRI.
The safety and efficacy of 12 days of pre-surgical sunitinib were investigated in the NeoSun
prospective clinical trial (EudraCT No: 2005-004502-82). Sunitinib was chosen as a well-inves-
tigated first-line agent in mRCC and for its potential as a neoadjuvant agent to reduce the
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volume of the primary tumor [13]. This report investigates the effects of pre-surgical sunitinib
therapy using quantitative, physiological and morphological MRI measurements and assesses
whether these can be used to detect early treatment response and predict overall and progres-
sion-free survival in the NeoSun cohort.
Materials and methods
Participant selection
Imaging data from the NeoSun trial, a prospective, single-centre, single-arm phase II study of
neoadjuvant sunitinib in mRCC, was assessed following a pre-planned analysis [14]. National
research ethics committee approval was obtained (REC ref: 2005-004502-82) and written
informed consent was provided by all study participants. Key inclusion criteria were histopath-
ological confirmation of clear cell RCC with metastases judged by the treating clinician to
potentially derive benefit from sunitinib prior to a planned cytoreductive nephrectomy. Partic-
ipants were excluded if they had undergone previous treatment for mRCC or were unable to
undergo MRI. Twenty-two consecutive participants were screened for inclusion in the trial
between 04/2011 and 01/2014. Six participants were excluded prior to enrolment and four par-
ticipants did not fulfil the criteria for study completion (see CONSORT diagram, Fig 1). This
Participants screened (n = 22)
Participants enrolled (n = 16)
Patients excluded (n = 6)
 - Not meeting inclusion criteria (n = 5)
 - Patient declined (n = 1)
Participants undergoing nephrectomy (n = 14)
Patients excluded (n = 2)
 - Resection of all target lesions (n = 1)
 - Completion of <2 cycles of treatment (n = 1)
Patients completing study (n = 12)
Patients excluded (n = 2)
 - Signicant adverse event (n = 1)
 - Pulmonary embolism before therapy (n = 1)
Fig 1. CONSORT diagram explaining recruitment and reasons for exclusion of participants.
https://doi.org/10.1371/journal.pone.0258988.g001
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manuscript reports the outcomes of the exploratory imaging endpoints of the NeoSun trial.
Primary oncological outcomes of the trial have been published elsewhere [14] and only partici-
pants who completed the full MR-imaging protocol are included in this report. One partici-
pant did not tolerate the MRI. The incomplete dataset was of poor quality and, therefore,
excluded from further analysis.
Treatment
All participants underwent treatment with 50 mg sunitinib once daily for 12 days prior to radi-
cal cytoreductive nephrectomy; one participant due additionally underwent bilateral adrenal-
ectomy for metastatic involvement. Sunitinib therapy was resumed after surgery on a
repeating 6-week cycle (4 weeks-on, 2 weeks-off) until RECIST 1.1 defined disease progression
was identified on 12-weekly follow-up CT, or patients experienced unacceptable toxicity, as
assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events,
Version 4.0 [15].
Survival
Overall survival (OS) was defined as the time between enrolment and the date of death from
any cause. Participants who were lost to follow-up were censored at the last date when they
were known to have been alive. Patients who were still alive on the 01/03/2020 were censored
on this date, resulting in a median follow-up of 2.6 years (range: 0.6–8 years) for all patients
and between 2.7 years and 8 years for surviving patients. Progression-free survival (PFS) was
defined as the time between enrolment and the date of RECIST 1.1 defined progressive disease,
or death from any cause.
MRI technique
Multiparametric MRI was acquired at baseline and after 12 days of pre-surgical sunitinib treat-
ment. Treatment response assessment was performed using contrast-enhanced CT of the tho-
rax, abdomen and pelvis at baseline and every three months following nephrectomy, until
disease progression.
MR imaging was performed on a 1.5 T Discovery MR450 system (GE Healthcare) using an
8-channel cardiac array coil. The multiparametric protocol included sagittal DWI using a
dual-spin-echo echo-planar imaging sequence and b-values of 0, 150, 500, 700 and 900 s/mm2
with TE 73.4 ms; TR 4000 ms; FoV 35x35 cm2; slice thickness/gap 4/1 mm; acquisition matrix
104x104; 6 Nex; receiver bandwidth ±250 kHz; ASSET factor 2; scan time 5 minutes 16 sec-
onds (Table 1). Trace-weighted images were acquired by averaging 3 orthogonal diffusion
directions for the non-zero b-values. Saturation bands were used to reduce signals from out-
side the volume of interest. Although no specific DWI performance characterisations were
performed for this specific study, the reliability of the body DWI measurements was carefully
characterised as part of another study conducted on the same MRI system and during an over-
lapping time-period [16]. The S1 File provides detailed acquisition information for the remain-
ing sequences. The median acquisition time was 61 minutes (table time, range 56–68
minutes). For the DCE-MRI acquisition, 0.1 mmol/kg of Gd-DOTA (Dotrarem, Guerbet) was
used.
Image processing
Analysis of the IVIM DWI data was performed using in-house developed software developed
in MATLAB (The Mathworks, version R2010b). The four non-zero b-values were used for
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voxelwise mono-exponential calculations of the diffusivity D. The perfusion fraction fp was
then estimated at a voxel level from the fractional difference between the measurements at
b = 0 s/mm2 and the extrapolated signal from the higher b-values. A repeatability coefficient of
20% was pre-defined as a threshold for the detection of treatment-related changes based on
existing literature describing the repeatability of ADC measurements [17–19].
In-house software developed in MATLAB was used to generate R2
� and T2
� maps from the
multi-echo gradient-echo images. The pixel-level data were fitted to a mono-exponential
decay using the nonlinear Levenberg–Marquardt algorithm, and using a log-linear approxima-
tion to compute the initial values for the fits.
The T1 mapping and DCE-MRI data were processed in MIStar (Apollo Medical Imaging
Technology). Each dataset was pre-processed using a 3x3 median filter. The T1 mapping and
DCE datasets were co-registered both within and between the datasets to remove (as far as pos-
sible) spatial mis-registrations induced by motion. The Tofts model [20] using a population-
averaged Arterial Input Function [21] was applied to calculate maps of the transfer constant
Ktrans and quantify the contrast-concentration-versus-time curve for 90 seconds after the
arrival of the contrast bolus (iAUC90).
Regions-of-interest (ROI) were outlined for the normal-appearing ipsilateral kidney, the
tumor and its necrotic/cystic parts by two radiologists with 8 (T.B.) and 5 (F.Z.) years of expe-
rience on the coronal T2w FRFSE sequence, the sagittal ADC map, the sagittal R2
� and coro-
nal-oblique Ktrans maps using ImageSetViewer Software, version 1.7 (University Health
Network Toronto). The segmentation was undertaken blinded to the clinical outcome and
RECIST measurements. The region of interest for the solid tumor components was generated
from the subtraction of the necrotic/cystic parts from the entire tumor. Using custom-written
MATLAB software, slice-wise ROIs were combined into whole volumes of interest and used to
calculate the volumes of each tumor component (from T2w imaging) and also the median val-
ues of Ktrans, iAUC90, R2�, fp and D within the whole and solid tumor components for each par-
ticipant. The test re-test variation in imaging parameters was compared in the normal renal
tissue to appraise the repeatability of quantitative imaging measurements in tissues not tar-
geted by sunitinib. A single radiologist (T.B.) performed the RECIST 1.1 assessment on the CT
scans acquired at baseline and following nephrectomy. The contrast-enhanced CT scans
Table 1. Imaging parameters.
Sequence TE / TR [ms] Flip Angle [deg] Matrix Size Slice Thickness / Orientation Other parameters
T2w FRFSE 48–69 / 4000 90 320 x 224 4 mm coronal ETL: 10–13, RT
1 mm gap 2 Nex
T1w FSPGR 4.8 / 139 70 256 x 256 4 mm coronal BH
1 mm gap 0.75 Nex, ASSET 2
DW-EPI 73.4/4000 90 104 x 104 4 mm sagittal b-values: 0, 150, 500, 700 and 900 s/mm2
(IVIM type) 1 mm gap 6 Nex, ASSET 2
R2
� mapping 4.76–47.6 (echo spacing 4.76) / 100 25 128 x 128 4 mm sagittal BH
1 mm gap ASSET 2
T1 mapping 1.6 / 3.9 1, 3, 5, 10, 15 and 20 160 x 160 5 mm coronal-oblique BH
1 Nex
DCE-MRI 1.6 / 3.9 18 160 x 160 5 mm coronal-oblique intermittent bh, temporal resolution: 4.3–6.4 s
0.5 Nex
TE: Echo Time, TR: Repetition Time, ETL: Echo Train Length, RT: respiratory triggered, BH: breath hold, DCE: dynamic contrast-enhanced, Nex: Number of
excitations.
https://doi.org/10.1371/journal.pone.0258988.t001
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covererd the chest, abdomen and pelvis and included metastatic lesions which were not
included in the field-of-view of the MRI scan which was restricted to the tumour-bearing
kidney.
Statistical methods
Statistical analysis was performed in the SAS suite (version 9.4). Differences before and after
therapy were assessed with the non-parametric Wilcoxon signed-rank test. Differences in sur-
vival were visualised using Kaplan-Meier plots and survival distributions compared using log-
rank tests. The Mann-Whitney U test was used for the comparison of unpaired samples. P
values� 0.05 were considered as statistically significant.
Results
The data of thirteen of the 22 participants screened for participation in this study was analyzed.
Twelve patients (1 female, 11 male) were included in this study (Fig 1). The median age at
enrolment was 60 years (range: 50–74, mean 61 years). The stage at nephrectomy was pT1b in
one patient, pT3a in 10 patients and pT3b in one patient. Five patients were diagnosed with
pN1 disease and all patients had cM1 disease. Participant characteristics are summarized in
Table 2.
Volumetric findings
At baseline, the mean volume of the primary tumor was 633 ml (SD ± 386 ml, range 175–1369
ml) of which 68% (15–95%) equivalent to 388 ml (± 249 ml, 104–903 ml,) was solid tumor tis-
sue. Following pre-surgical treatment with sunitinib for 12 days, an average reduction of 25%
to 507 ml (± 351 ml, 90–1213 ml) was observed in the total tumor volume (p< 0.001, df = 11,
Table 2. Participant characteristics.
Characteristic n = 12
Age at enrolment (mean ± SD) 61 ± 7.6 years
















Overall Survival (median [range]) 138 weeks [30–417]
Progression-free survival (median [range]) 67 weeks [17–417]
SD: Standard deviation.
https://doi.org/10.1371/journal.pone.0258988.t002
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V = 78, previously reported [14]). Concurrently, the average volume of solid tissue decreased
by 28% to 295 ml (± 217 ml, 81–749 ml), p< 0.001 (df = 11, V = 78), with the volume of
necrotic/cystic tumor components only reducing by 17%, from 245 ml (± 263 ml, 10–885 ml)
to 212 ml (± 251 ml, 8–830 ml), p = 0.005 (df = 11, V = 74). Furthermore, tumor necrosis was
associated with decreased response to pre-surgical therapy with a negative correlation between
the percentage of necrotic tumor volume at baseline and the overall reduction in tumor vol-
ume after 12 days of sunitinib therapy (Spearman rank correlation coefficient ρ = -0.69, 95%-
CI: 0.10–0.97, p = 0.02). However, neither the reduction in whole tumor volume nor a solid
tumor volume was associated with PFS and OS (Fig 2a/2b). The reduction in volume of the
tumor was not associated with the overall RECIST response of the residual metastatic tumor
burden following surgery (Fig 3A and 3B). There was a trend for objective response according
to RECIST (partial or complete response as best RECIST response) being associated with lon-
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Strata | |< Median > Median tumour diffusivity reduction
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Strata | |< Median > Median tumour volume reduction
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Fig 2. Kaplan Meier survival curves showing no overall survival benefit for participants with larger than median relative tumour volume reduction following 12 days of
pre-surgical sunitinib therapy, however, there was a trend for participants with less volume reduction to survive longer (a). No difference in PFS was observed (b)
Participants with a larger reduction in tumour diffusivity D experienced longer PFS (c) while there was a trend for participants with objective response according to
RECIST 1.1 (partial or complete response) to show longer PFS than patients without objective response (stable or progressive disease) (d). P-values for log-rank test.
https://doi.org/10.1371/journal.pone.0258988.g002
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Diffusion-weighted imaging
Following pre-surgical treatment, a reduction of the median diffusivity D of the solid tumor by
7.7% from 1298 x 10−6 mm2/s to 1200 x 10−6 mm2/s was observed (p = 0.02, df = 11, V = 68).
Only two patients achieved a greater than 20% change in D, which was the a priori defined
threshold for treatment effect in an individual patient. However, a greater than median reduc-
tion in solid tumor D was associated with prolonged PFS (p = 0.031), median PFS 183 weeks
vs. 48 weeks, Fig 2D). The baseline D was not predictive of OS or PFS and the reduction in D
was not predictive of OS. Concurrently, the perfusion fraction of the solid tumor decreased by
19% from 0.24 to 0.19 (p< 0.001), however, a reduction in perfusion fraction exceeding the
predetermined cut-off of 20% was not predictive of prolonged OS (p = 0.88).
The change in mean tumor diffusivity D between baseline and follow-up showed a differen-
tial response between participants, with an 11% reduction in patients demonstrating an objec-
tive response according to RECIST (partial or complete response; n = 9), and a 3% increase for
non-responders (n = 3);. Fig 3C The perfusion fraction fp was not able to differentiate between
responders and non-responders and neither D nor fp was associated with long-term treatment
benefits.
Blood oxygenation dependent imaging
The median R2
� from BOLD MRI increased within the solid parts of the tumor from 19 s-1 to
28 s-1 (p = 0.001, df = 11). However, an R2� at baseline above the median did not predict OS and
PFS and the increase in R2� was not associated with improved response according to RECIST.
T1 map
A post-hoc analysis showed a median T1 of 1238 ms (interquartile range: 1184–1341) in the
solid tumour at baseline which reduced to 1102 ms (994–1221 ms) after 12 days of sunitinib.
Fig 3. Treatment related changes: Percentage change in the whole tumour volume (a), solid tumour volume (b), solid
tumour Diffusivity D (c), solid tumour Ktrans (d), solid tumour R2� (e) and solid tumour perfusion fraction (f) between
patients with stable/progressive disease (SD/PD) and partial/complete response (PR/CR). P-values for Mann-Whitney
U test. Relative changes in normal renal tissue illustrate the test re-test variability in imaging measurements.
https://doi.org/10.1371/journal.pone.0258988.g003
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The median reduction by 6% was not significant (p = 0.094). Neither the tumour T1 at baseline
nor its change following treatment was associated with the RECIST response or survival.
Dynamic contrast-enhanced imaging
Median Ktrans and iAUC90 both showed significant decreases within solid tumor components
following treatment initiation, with a mean reduction in Ktrans from 0.415 min-1 to 0.305 min-1
(28% reduction, previously reported [14]), and of iAUC90 from 0.55 to 0.36 mM min (38%
reduction), respectively (p = 0.01 and 0.003, df = 11, V = 71 and 78).
Nine participants had a reduction in Ktrans greater than the pre-determined repeatability
coefficient of 20% which was selected based on existing literature [22, 23] and is in agreement
with more recent findings [24]. However, these participants did not derive an overall or PFS
benefit from this.
A typical example of the evolution of all physiological imaging parameters during the pre-
surgical sunitinib treatment can be seen in Fig 4.
Discussion
This study showed that early treatment response to pre-surgical sunitinib in RCC can be
detected after 12 days using multiparametric MRI and that changes in diffusivity are associated
with the volumetric response to treatment and progression-free survival. The data for this study
was gathered in a prospective clinical trial where treatment and imaging were tightly controlled
and the consistent timing of the follow-up MRI relative to the start of treatment was critical for
assessing the early treatment response. Furthermore, the physiological parameters investigated
in this study were functionally linked to the mechanism of action of sunitinib and could, there-
fore, report on the engagement of the drug with its target. The imaging data were acquired on a
single MRI-scanner, eliminating inter-scanner variability as a confounding factor.
The reduction in tumor volume following sunitinib therapy was greatest in the solid tumor
fraction. This may aid treatment planning with initial neo-adjuvant systemic therapy acting to
debulk tumor volume in patients with large tumors, to reduce surgical challenges and risks. In
these patients, the presence of large solid tumor components would suggest that a chemore-
duction prior to cytoreductive surgery may be feasible with a short course of TKI therapy. Fur-
thermore, the decrease in solid tumor volume could serve as a sensitive biomarker of
treatment response. However, only the reduction in diffusivity was associated with PFS, with
significant reductions in excess of 20% from the baseline values being observed in two patients.
This result will need validation in future, larger cohorts and if confirmed, this imaging
approach might be particularly relevant in localized disease where surgery is more impactful as
a cure.
The changes observed in physiological imaging parameters were compatible with the
expected mechanism of action of sunitinib. Consequently, these widely available MRI tech-
niques could be useful surrogate markers for confirming successful engagement of anti-angio-
genic agents with their biological target. Consistently, the perfusion fraction on IVIM-type
DWI was reduced, representing a decrease in capillary volume; this was, however, not corre-
lated with survival. This is expected given the decreased activation of the vascular endothelial
growth factor receptors (VEGFR1 –VEGFR3) which leads to reduced angiogenesis and vascu-
lar maintenance [25]. Furthermore, the R2
� was increased, representing decreased oxygenation
and vascularization, and the DCE transfer constant Ktrans and area under the contrast-
enhancement curve (iAUC90) were decreased, signifying decreased perfusion and vascular per-
meability following treatment. These imaging surrogates were in agreement with the decrease
in immunohistochemical microvessel density observed in the same patient cohort [14].
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Previous attempts at predicting treatment outcome in patients undergoing 15 days of suni-
tinib treatment for mRCC have shown an increased time-to-peak using contrast-enhanced
ultrasound (CEUS). This was correlated with the RECIST response after 12 weeks, PFS and OS
in a cohort of 38 patients [26]. However, follow-up results including a multi-center study
involving 157 patients were not able to confirm these initial results [27, 28]. Contrary to these
studies, sunitinib was the first-line treatment in all patients in NeoSun. MRI, as opposed to
CEUS, has several advantages. It is operator-independent and the larger field-of-view allows
imaging of the entire tumor volume and potentially multiple metastatic deposits in addition.
This is particularly advantageous in mRCC where the response to TKI is known to show intra-
patient heterogeneity [29]. Finally, CEUS is reliant on having a good acoustic window and little
respiratory motion of the target lesion during the three-minute acquisition.
A larger post-treatment reduction in diffusivity of the solid component of the primary
tumor was associated with a better RECIST response in the metastatic burden and longer PFS.
The overall diffusion restriction increased, despite increasing histological necrosis which acts
to increase ADC values [14]. Other studies have demonstrated increases in ADC values after
three days of treatment which returned to baseline after ten days and remained unaltered after
3–4.5 months [30, 31]. In the current study, diffusivity was assessed in solid tumor compo-
nents, while the others analyzed the entire tumor. Given the very heterogeneous nature of
RCC, measuring the true diffusivity change following treatment is difficult. The assessment of
the solid components alone is likely to be the most accurate measure of the response to therapy
in the viable tumor. Furthermore, IVIM-type DWI provided information on diffusion restric-
tion and relative capillary volume simultaneously, whereas previous studies investigated ADC,
an aggregate of tissue diffusion and microperfusion [30, 31]. It is conceivable that these param-
eters undergo sequential changes as the tissue becomes edematous, necrotic, and is then
restructured [31]. Furthremore, sunitinib is associated with increasing infiltration of tumour
with CD8+ T-cells, which may also lead to a reduction in diffusivity [32]. However, repeat dif-
fusion-weight imaging at more frequent intervals would be needed to resolve these temporal
changes.
This study has several limitations, including the small number of patients, however, this is
similar to previous literature investigating multiparametric MRI in patients with RCC [33, 34].
The study was stopped ahead of its recruitment target due to slow participant accrual, conse-
quently, the statistical power was decreased. As a single center trial, this will require indepen-
dent validation to determine generalizability. Furthermore, recent results have shown that
cytoreductive nephrectomy in metastatic RCC needs to be considered carefully and is most
appropriate in patients with low-volume metastatic disease [3]. In particular, the correlation of
imaging biomarkers with OS, a secondary aim of the NeoSun trial, should be investigated in
an appropriately powered trial. Recent data has shown that mono-exponential fitting of D0
should employ b-values> 200 s/mm2 to avoid contributions from tissue perfusion [35]. As the
data for NeoSun was acquired prior to this publication, the lowest b-value was 150 s/mm2 and
perfusion may have had a minor contribution to the overall signal.
Treatment monitoring on standard-of-care CT alone is challenging as tumor size is a late
sign of response. In this study, the physiological parameters Ktrans, R2
� and fp, which are
Fig 4. Examples of the multiparametric MRI before and after 12 days of sunitinib therapy in a 52 year-old male patient. The
parametric maps before and after therapy are windowed equally. This patient showed an overall tumour volume reduction of 14%,
with a decrease in volume of the solid tumour fraction by 33% and an increase in the necrotic/cystic tumour fraction of 8% after two
weeks of therapy. Additionally, there was a reduction in diffusivity and perfusion fraction as well as an increase in R2
� in the solid
tumour component. Ktrans decreased post-therapy, which is consistent with the mechanism of action of sunitinib and representative of
most of the study patients. D map (diffusivity) and Perfusion fraction from IVIM-type DWI, Ktrans: Contrast transfer constant, R2�:
effective transverse relaxation rate, T2w: T2-weighted image.
https://doi.org/10.1371/journal.pone.0258988.g004
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sensitive to the antiangiogenic effect of TKIs, were significantly altered during early sunitinib
treatment. Together with metabolic imaging and radiomics, they can serve as candidate fea-
tures in future research. Further research on larger cohorts is required to determine the ability
of early treatment response detected by MRI to guide treatment decision making and optimize
the time-frame of effective therapy.
In conclusion, we demonstrate measurable changes in MRI features which are consistent
with the proposed mechanism of action of multi-targeted receptor tyrosine kinase inhibitors,
which were measurable after only 12 days of sunitinib therapy and related to the best response
according to RECIST and PFS.
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